| abstract |
The present invention relates to a compound of formula 1 or a pharmaceutically active salt thereof: Formula 1 Where XY is -N (R 2 ) -CH (R 3 )-, -CH (R 3 ) -N (R 2 )-, -NH-NH-, -O-CHR 3- , -CHR 3 -O-, -S-CHR 3- , -CHR 3 -S- or -CHR 3 -CHR 3 ' -; R 1 is hydrogen, halogen, lower alkyl, lower alkoxy,-(CH 2 ) o -phenyl optionally substituted with lower alkoxy,-(CH 2 ) o -C (O) -phenyl optionally substituted with lower alkoxy, -(CH 2 ) o -O-phenyl,-(CH 2 ) o -O-phenyl, CF 3 , cycloalkyl, NO 2 , amino or hydroxy, optionally substituted with lower alkoxy; R 2 is hydrogen, lower alkyl, phenyl optionally substituted with hydroxy, or benzyl; R 3 and R 3 ′ are independently of each other hydrogen, lower alkyl or benzyl; Ar is phenyl, naphthyl, benzofuranyl or benzo [1,3] dioxolyl; n is 1, 2, 3 or 4; o is 0, 1, 2 or 3. It has been found that the compound of formula 1 has a good affinity for trace amine bond receptors (TAAR), in particular TAAR1. The compounds include depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative diseases such as Alzheimer's disease, epilepsy , Migraine, high blood pressure, substance abuse or metabolic disorders such as eating disorders, diabetes mellitus, diabetic complications, obesity, dyslipidemia, disorders of energy consumption or assimilation, disorders or dysfunctions of body temperature homeostasis, disorders of sleep or circadian rhythms, or It can be used to treat cardiovascular disease. |